Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-04-26

AUTHORS

Anna Sophia Posawetz, Christian Trummer, Marlene Pandis, Felix Aberer, Thomas R. Pieber, Barbara Obermayer-Pietsch, Stefan Pilz, Verena Theiler-Schwetz

ABSTRACT

BackgroundHyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline.MethodsCase-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy.Results21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107–147.5) vs. 94.5 (80–127.5) mg/dl, p < 0.001) were significantly higher, levels of HDL (56 ± 16.7 vs. 69.2 ± 14.6 mg/dl, p = 0.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups.After a median of 10 weeks (IQR 7–18 weeks) after initiation of cabergoline, total (from 212.5 ± 36.2 to 196.9 ± 40.6 mg/dl, p = 0.018) and LDL cholesterol (130 (107–147.5) to 106.5 (94.3–148) mg/dl, p = 0.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only.ConclusionsReasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients. More... »

PAGES

81

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6

DOI

http://dx.doi.org/10.1186/s12902-021-00733-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1137484146

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33902531


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adiposity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Austria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Composition", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Mass Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cabergoline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dyslipidemias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperprolactinemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lipid Metabolism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Overweight", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pituitary Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prolactinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Posawetz", 
        "givenName": "Anna Sophia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trummer", 
        "givenName": "Christian", 
        "id": "sg:person.01201252150.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201252150.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pandis", 
        "givenName": "Marlene", 
        "id": "sg:person.015231525635.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015231525635.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aberer", 
        "givenName": "Felix", 
        "id": "sg:person.01351004310.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351004310.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pieber", 
        "givenName": "Thomas R.", 
        "id": "sg:person.0757263437.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757263437.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Obermayer-Pietsch", 
        "givenName": "Barbara", 
        "id": "sg:person.01071524655.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071524655.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pilz", 
        "givenName": "Stefan", 
        "id": "sg:person.0751717266.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751717266.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Theiler-Schwetz", 
        "givenName": "Verena", 
        "id": "sg:person.011457756430.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011457756430.96"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11011-016-9882-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034492836", 
          "https://doi.org/10.1007/s11011-016-9882-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12020-012-9857-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032398967", 
          "https://doi.org/10.1007/s12020-012-9857-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03345636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028831522", 
          "https://doi.org/10.1007/bf03345636"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-04-26", 
    "datePublishedReg": "2021-04-26", 
    "description": "BackgroundHyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline.MethodsCase-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy.Results21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107\u2013147.5) vs. 94.5 (80\u2013127.5) mg/dl, p\u2009<\u20090.001) were significantly higher, levels of HDL (56\u2009\u00b1\u200916.7 vs. 69.2\u2009\u00b1\u200914.6\u2009mg/dl, p\u2009=\u20090.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups.After a median of 10\u2009weeks (IQR 7\u201318\u2009weeks) after initiation of cabergoline, total (from 212.5\u2009\u00b1\u200936.2 to 196.9\u2009\u00b1\u200940.6\u2009mg/dl, p\u2009=\u20090.018) and LDL cholesterol (130 (107\u2013147.5) to 106.5 (94.3\u2013148) mg/dl, p\u2009=\u00a00.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only.ConclusionsReasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12902-021-00733-6", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1028426", 
        "issn": [
          "1472-6823"
        ], 
        "name": "BMC Endocrine Disorders", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "initiation of cabergoline", 
      "fat mass", 
      "metabolic parameters", 
      "body composition", 
      "lipid metabolism", 
      "MethodsCase-control study", 
      "dopamine agonist therapy", 
      "adverse body composition", 
      "increased cardiovascular risk", 
      "adverse metabolic effects", 
      "levels of HDL", 
      "higher fat mass", 
      "levels of LDL", 
      "case-control study", 
      "Altered lipid metabolism", 
      "cabergoline therapy", 
      "untreated patients", 
      "HOMA-IR", 
      "cardiovascular risk", 
      "LDL cholesterol", 
      "lipid parameters", 
      "higher BMI", 
      "metabolic effects", 
      "prolactinomas", 
      "patients", 
      "adipose tissue", 
      "cabergoline", 
      "therapy", 
      "men", 
      "prolactin", 
      "only men", 
      "women", 
      "direct effect", 
      "metabolism", 
      "glucose", 
      "initiation", 
      "HbA1c", 
      "adiponectin", 
      "BMI", 
      "hypogonadism", 
      "group", 
      "LDL", 
      "control", 
      "CRP", 
      "HDL", 
      "cholesterol", 
      "homocysteine", 
      "weeks", 
      "ConclusionsReasons", 
      "study", 
      "median", 
      "levels", 
      "total", 
      "risk", 
      "tissue", 
      "association", 
      "effect", 
      "aim", 
      "changes", 
      "mass", 
      "sites", 
      "parameters", 
      "necessity", 
      "composition"
    ], 
    "name": "Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study", 
    "pagination": "81", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1137484146"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12902-021-00733-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33902531"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12902-021-00733-6", 
      "https://app.dimensions.ai/details/publication/pub.1137484146"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_917.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12902-021-00733-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      112 URIs      101 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12902-021-00733-6 schema:about N0a3339142c5f41f99c23d2f44ffb3b85
2 N1123c916943a4a80add4c4ba59e39850
3 N38f7e7025ca6406f9b4d339433fd2d60
4 N4abf87a4bf6e4c718652850dd8944cf7
5 N584187aee9f34090b163ffe5807541dc
6 N63bec533ec254cf79eb90cc0341bfc98
7 N713ac3e227944146bf8ae75d4d0572d6
8 N74f8d5ba11ce47b786992323e69b9e34
9 N7fa95bafde6c4b78a0f32dd53a067255
10 N85dbe116b0fb4f888dc94adce0a1db80
11 N926e289b16b54757a91d6e4fe6e12f8b
12 N94b02b432c6c404d86a1cb0b7627021f
13 N971ee563d55e494fb833fc29f4edbdb3
14 N9d83d8fd66744b4d927e2d45ea140de8
15 Na4fc7265380847f6a837d51b28310a41
16 Ncb2de11aff9745c689bfbf3b89a5bd0e
17 Nd5dd178bc55349eb850f7f7415f6eaa0
18 Nd7afeca38aae4321b55478abc4f4017e
19 Nf906bc6027f44ae890556de724562294
20 Nfa66e2e9a988472884a4df0febf855e5
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author Na821aabe8c6047a39cd73ee1b21c3f4d
24 schema:citation sg:pub.10.1007/bf03345636
25 sg:pub.10.1007/s11011-016-9882-2
26 sg:pub.10.1007/s12020-012-9857-y
27 schema:datePublished 2021-04-26
28 schema:datePublishedReg 2021-04-26
29 schema:description BackgroundHyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline.MethodsCase-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy.Results21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107–147.5) vs. 94.5 (80–127.5) mg/dl, p < 0.001) were significantly higher, levels of HDL (56 ± 16.7 vs. 69.2 ± 14.6 mg/dl, p = 0.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups.After a median of 10 weeks (IQR 7–18 weeks) after initiation of cabergoline, total (from 212.5 ± 36.2 to 196.9 ± 40.6 mg/dl, p = 0.018) and LDL cholesterol (130 (107–147.5) to 106.5 (94.3–148) mg/dl, p = 0.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only.ConclusionsReasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients.
30 schema:genre article
31 schema:isAccessibleForFree true
32 schema:isPartOf Nddcd73c7b19041fe8753f583d35b4360
33 Nf3a6da330a04405ab5aeb71da13bf50c
34 sg:journal.1028426
35 schema:keywords Altered lipid metabolism
36 BMI
37 CRP
38 ConclusionsReasons
39 HDL
40 HOMA-IR
41 HbA1c
42 LDL
43 LDL cholesterol
44 MethodsCase-control study
45 adiponectin
46 adipose tissue
47 adverse body composition
48 adverse metabolic effects
49 aim
50 association
51 body composition
52 cabergoline
53 cabergoline therapy
54 cardiovascular risk
55 case-control study
56 changes
57 cholesterol
58 composition
59 control
60 direct effect
61 dopamine agonist therapy
62 effect
63 fat mass
64 glucose
65 group
66 higher BMI
67 higher fat mass
68 homocysteine
69 hypogonadism
70 increased cardiovascular risk
71 initiation
72 initiation of cabergoline
73 levels
74 levels of HDL
75 levels of LDL
76 lipid metabolism
77 lipid parameters
78 mass
79 median
80 men
81 metabolic effects
82 metabolic parameters
83 metabolism
84 necessity
85 only men
86 parameters
87 patients
88 prolactin
89 prolactinomas
90 risk
91 sites
92 study
93 therapy
94 tissue
95 total
96 untreated patients
97 weeks
98 women
99 schema:name Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study
100 schema:pagination 81
101 schema:productId N2733ac16bb31467fb644eb2eba60004a
102 N2edd611c186d47edbe8ece3dc0877819
103 N52159c93288646d0aa42ead5deb660f3
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137484146
105 https://doi.org/10.1186/s12902-021-00733-6
106 schema:sdDatePublished 2022-12-01T06:43
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N4a24541f15024b0cb70eb67d57c8e802
109 schema:url https://doi.org/10.1186/s12902-021-00733-6
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N0a3339142c5f41f99c23d2f44ffb3b85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Young Adult
115 rdf:type schema:DefinedTerm
116 N1123c916943a4a80add4c4ba59e39850 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Hyperprolactinemia
118 rdf:type schema:DefinedTerm
119 N2733ac16bb31467fb644eb2eba60004a schema:name dimensions_id
120 schema:value pub.1137484146
121 rdf:type schema:PropertyValue
122 N2edd611c186d47edbe8ece3dc0877819 schema:name doi
123 schema:value 10.1186/s12902-021-00733-6
124 rdf:type schema:PropertyValue
125 N38f7e7025ca6406f9b4d339433fd2d60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Female
127 rdf:type schema:DefinedTerm
128 N4a24541f15024b0cb70eb67d57c8e802 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N4abf87a4bf6e4c718652850dd8944cf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Adiposity
132 rdf:type schema:DefinedTerm
133 N52159c93288646d0aa42ead5deb660f3 schema:name pubmed_id
134 schema:value 33902531
135 rdf:type schema:PropertyValue
136 N584187aee9f34090b163ffe5807541dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Case-Control Studies
138 rdf:type schema:DefinedTerm
139 N60682bc5ce0149f3b20fb92f4acf1830 rdf:first sg:person.01201252150.71
140 rdf:rest Nfc1a634bce544c33b6c1515c495e94d1
141 N631d1678f26e491089cc09bd40d48bdd rdf:first sg:person.0751717266.10
142 rdf:rest N8c598c950664462196075df95b0a7d7f
143 N63bec533ec254cf79eb90cc0341bfc98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Retrospective Studies
145 rdf:type schema:DefinedTerm
146 N652210dbc0724ffe8607eff52a207dec schema:affiliation grid-institutes:grid.11598.34
147 schema:familyName Posawetz
148 schema:givenName Anna Sophia
149 rdf:type schema:Person
150 N713ac3e227944146bf8ae75d4d0572d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Lipid Metabolism
152 rdf:type schema:DefinedTerm
153 N74f8d5ba11ce47b786992323e69b9e34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Dyslipidemias
155 rdf:type schema:DefinedTerm
156 N7fa95bafde6c4b78a0f32dd53a067255 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Male
158 rdf:type schema:DefinedTerm
159 N85dbe116b0fb4f888dc94adce0a1db80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Austria
161 rdf:type schema:DefinedTerm
162 N8c598c950664462196075df95b0a7d7f rdf:first sg:person.011457756430.96
163 rdf:rest rdf:nil
164 N926e289b16b54757a91d6e4fe6e12f8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Pituitary Neoplasms
166 rdf:type schema:DefinedTerm
167 N94b02b432c6c404d86a1cb0b7627021f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Adult
169 rdf:type schema:DefinedTerm
170 N971ee563d55e494fb833fc29f4edbdb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Humans
172 rdf:type schema:DefinedTerm
173 N9d83d8fd66744b4d927e2d45ea140de8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Cabergoline
175 rdf:type schema:DefinedTerm
176 Na4fc7265380847f6a837d51b28310a41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Prolactinoma
178 rdf:type schema:DefinedTerm
179 Na5f3cc7ba16d41f8b7d109d0c7bd5bc4 rdf:first sg:person.01071524655.82
180 rdf:rest N631d1678f26e491089cc09bd40d48bdd
181 Na821aabe8c6047a39cd73ee1b21c3f4d rdf:first N652210dbc0724ffe8607eff52a207dec
182 rdf:rest N60682bc5ce0149f3b20fb92f4acf1830
183 Ncb2de11aff9745c689bfbf3b89a5bd0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Body Composition
185 rdf:type schema:DefinedTerm
186 Nd5dd178bc55349eb850f7f7415f6eaa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Middle Aged
188 rdf:type schema:DefinedTerm
189 Nd7afeca38aae4321b55478abc4f4017e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Follow-Up Studies
191 rdf:type schema:DefinedTerm
192 Nddcd73c7b19041fe8753f583d35b4360 schema:volumeNumber 21
193 rdf:type schema:PublicationVolume
194 Nf3a6da330a04405ab5aeb71da13bf50c schema:issueNumber 1
195 rdf:type schema:PublicationIssue
196 Nf51bb4c569634cde9ec1d2f0c074ec0a rdf:first sg:person.0757263437.98
197 rdf:rest Na5f3cc7ba16d41f8b7d109d0c7bd5bc4
198 Nf906bc6027f44ae890556de724562294 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Overweight
200 rdf:type schema:DefinedTerm
201 Nfa66e2e9a988472884a4df0febf855e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Body Mass Index
203 rdf:type schema:DefinedTerm
204 Nfc1a634bce544c33b6c1515c495e94d1 rdf:first sg:person.015231525635.58
205 rdf:rest Nfc57267d09254ec2a69c9609aa1766ce
206 Nfc57267d09254ec2a69c9609aa1766ce rdf:first sg:person.01351004310.93
207 rdf:rest Nf51bb4c569634cde9ec1d2f0c074ec0a
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
212 schema:name Clinical Sciences
213 rdf:type schema:DefinedTerm
214 sg:journal.1028426 schema:issn 1472-6823
215 schema:name BMC Endocrine Disorders
216 schema:publisher Springer Nature
217 rdf:type schema:Periodical
218 sg:person.01071524655.82 schema:affiliation grid-institutes:grid.11598.34
219 schema:familyName Obermayer-Pietsch
220 schema:givenName Barbara
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071524655.82
222 rdf:type schema:Person
223 sg:person.011457756430.96 schema:affiliation grid-institutes:grid.11598.34
224 schema:familyName Theiler-Schwetz
225 schema:givenName Verena
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011457756430.96
227 rdf:type schema:Person
228 sg:person.01201252150.71 schema:affiliation grid-institutes:grid.11598.34
229 schema:familyName Trummer
230 schema:givenName Christian
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201252150.71
232 rdf:type schema:Person
233 sg:person.01351004310.93 schema:affiliation grid-institutes:grid.11598.34
234 schema:familyName Aberer
235 schema:givenName Felix
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351004310.93
237 rdf:type schema:Person
238 sg:person.015231525635.58 schema:affiliation grid-institutes:grid.11598.34
239 schema:familyName Pandis
240 schema:givenName Marlene
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015231525635.58
242 rdf:type schema:Person
243 sg:person.0751717266.10 schema:affiliation grid-institutes:grid.11598.34
244 schema:familyName Pilz
245 schema:givenName Stefan
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751717266.10
247 rdf:type schema:Person
248 sg:person.0757263437.98 schema:affiliation grid-institutes:grid.11598.34
249 schema:familyName Pieber
250 schema:givenName Thomas R.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757263437.98
252 rdf:type schema:Person
253 sg:pub.10.1007/bf03345636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028831522
254 https://doi.org/10.1007/bf03345636
255 rdf:type schema:CreativeWork
256 sg:pub.10.1007/s11011-016-9882-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034492836
257 https://doi.org/10.1007/s11011-016-9882-2
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/s12020-012-9857-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1032398967
260 https://doi.org/10.1007/s12020-012-9857-y
261 rdf:type schema:CreativeWork
262 grid-institutes:grid.11598.34 schema:alternateName Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria
263 schema:name Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...